Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cetaphil DermaControl Foam Wash and Moisturizer SPF 30 is a specialized skincare regimen developed by Galderma for the management of acne-prone skin. The regimen consists of a foaming facial cleanser and a daily moisturizer. The foam wash utilizes zinc technology to remove excess oil and soothe the skin without compromising the skin barrier. The moisturizer provides broad-spectrum UVA/UVB protection using Oleosome technology, which allows for lower concentrations of sunscreen filters to reduce irritation. It also features Micropearl technology to absorb surface oil for a matte finish and ceramide technology to help restore and maintain the skin's natural moisture barrier. This product line is designed to be used as an adjunct to prescription acne treatments to improve patient compliance and skin tolerability.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cetaphil DermaControl Foam Wash and Moisturizer SPF 30.